Effects of Surgery Combined with Different Chemotherapy on Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinase-1 in Children with Neuroblastoma

Table 1

Chemotherapy regimen.

CAV	Cyclophosphamide (CTX) 750–1000 mg/m^2 i.v. d1; Jiangsu Hengrui Medicine Co., Ltd., H32020857; Vincristine (VCR) 1.5 mg/m^2 i.v. d1; Guangdong Lingnan Pharmacy Co., Ltd., H20065857; Adriamycin (ADM) 50 mg/m^2 i.v. d1; Yabao Pharmaceutical Co., Ltd., H20010554	Courses 1, 3, and 5
EP	Etoposide (VP16) 60–80 mg/m^2 i.v. d1–d5; Qilu Pharmaceutical Co., Ltd., H37023182; Cisplatin (DDP) 20 mg/m^2 i.v. d1–d5; Yunnan Phytopharmaceutical Co., Ltd., H53021740	Courses 2, 4, and 5
TOPO	Topology (TOPO) 1.2 mg/m^2 i.v. d1–d5; Jiangsu Hengrui Medicine Co., Ltd., H20000438	Courses 1 and 2
CTX	CTX 250 mg/m^2 i.v.gtt d1–d5	Courses 1 and 2
CiE	DDP 50 mg/m^2 i.v.gtt d1–d4; VP16 200 mg/m^2 i.v.gtt d1–d3	Courses 3 and 5
CPV	CTX 2.1 g/m^2 i.v. gtt 48 h; Pirarubicin 25 g/m^2 i.v. gtt 48 h; Shenzhen Main Luck Pharmaceutical Co., Ltd., H10930106; VCR 0.67 mg/m^2 i.v.gtt 72 h	Courses 4 and 6
CV	CTX 5 mg/kg d1–d5; VCR 0.05 mg/kg d1